Hypothalamic Obesity
📧 Sign up to get email alerts when something new happens for Hypothalamic Obesity.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-12Clinical Trial Update: A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) [Phase 3]
Phase 3 trial update of setmelanotide for congenital hypothalamic obesity, including related pituitary hormone deficiency conditions, curren…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) [Phase 2]
Phase 2 long-term study of bivamelagon in hypothalamic obesity is currently enrolling by invitation.
-
CLINICAL_TRIALS research · 2025-12-22Clinical Trial Update: A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment [Phase 1, Phase 2]
A Clinical Trial Update indicates RM-718 is being studied in Phase 1/Phase 2 in healthy subjects and patients with MC4R pathway impairment, …
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Tirzepatide in PWS, HO and GNSO [Phase 4]
Phase 4 clinical trial evaluating tirzepatide for Prader-Willi Syndrome and hypothalamic obesity is currently recruiting.
-
CLINICAL_TRIALS research · 2025-07-02Clinical Trial Update: A Trial of Setmelanotide in Acquired Hypothalamic Obesity [Phase 3]
Rhythm Pharmaceuticals provides an update on a Phase 3 trial of setmelanotide for hypothalamic obesity, with the study currently active but …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.